Clinical trial
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
NCT00326495 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00326495 |
|---|---|
| Title | BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer |
| Official title | A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux ) in EGFR Expressing Metastatic Colorectal Cancer (CRC) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Cetuximab, BAY 43-9006 |
| Enrollment | 51 |
| Start date | May 10, 2006 |
| Primary completion | Nov 5, 2014 |
| Completion | Nov 7, 2014 |
| First posted | May 17, 2006 |
| Last update posted | Jul 24, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: